Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track STRO with free AI briefings, catalyst countdowns, and dilution alerts.

STRO · SUTRO BIOPHARMA, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$142.2M Cash on Hand
14mo Cash Runway
Follow STRO by email Get an email when STRO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about STRO, unsubscribe in one click. Privacy

📣 What STRO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Luveltamab Tazevibulin (STRO-002) Ovarian Cancer Phase 2/3 · NCT05870748 Terminated
Pegylated Liposomal Doxorubicin Hydrochloride Ovarian Cancer Phase 2/3 · NCT05870748 Terminated
Bezetabart Debotansine (STRO-001) B-cell Lymphoma Phase 1 · NCT03424603 Completed
Anti-TF/Exatecan Antibody-drug Conjugate… Head and Neck Squamous Cell Carcinoma HNSCC Phase 1 · NCT07227168 Recruiting
STRO-006 Head & Neck Squamous Cell Carcinoma Phase 1 · NCT07807345 Recruiting

Also used in these trials (approved or third-party drugs, not STRO's own candidates): Gemcitabine Hydrochloride, Paclitaxel, Pegfilgrastim, Topotecan, Bevacizumab, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

STRO holds $142.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $30.4M/quarter from operations, an estimated runway of 14 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 43 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when STRO files for a raise →

👥 Who Owns STRO

Insiders 0.7% Other 5%+ holders 6.4% Institutions (146 holders) 92.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
Perceptive Advisors LLC Institution (13G, 5%+) 1,304,846 7.86% 2026-06-30
BVF PARTNERS L P/IL Institution (13G, 5%+) 1,251,788 7.54% 2026-02-10
Affinity Asset Advisors, LLC Institution (13G, 5%+) 1,069,519 6.44% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 1,065,366 6.42% 2026-06-30
Srinivas Akkaraju 5%+ holder (13G) 1,062,872 6.40% 2026-02-11
Coastlands Capital LP Institution (13G, 5%+) 852,669 5.14% 2026-11-05
Connie Matsui
Director · +11,500 options
Insider 50,000 0.30% 2025-10-15
Jane Chung
Chief Executive Officer, Director · +248,938 options
Insider 21,285 0.13% 2026-03-04
Barbara Leyman
Chief Business Officer · +75,000 options
Insider 16,056 0.10% 2025-07-08
Hans-Peter Gerber
CHIEF SCIENTIFIC OFFICER · +67,457 options
Insider 12,367 0.07% 2026-09-18
David Pauling
Chief Admin. Ofcr. & GC · +54,255 options
Insider 9,748 0.06% 2026-03-04
Gregory K. Chow
CFO · +60,700 options
Insider 4,725 0.03% 2026-06-02

Share count 16,601,411 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full STRO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for STRO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.